GC
LEGN icon

Guggenheim Capital’s Legend Biotech LEGN Stock Holding History

Guggenheim Capital’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$756K Sell
26,189
-11,659
-31% -$314K ﹤0.01% 1125
2026
Q1 		$685K Sell
37,848
-6,259
-14% -$119K 0.01% 1112
2025
Q4 		$959K Buy
44,107
+8,649
+24% +$248K 0.01% 975
2025
Q3 		$1.16M Buy
35,458
+2,871
+9% +$106K 0.01% 870
2025
Q2 		$1.16M Sell
32,587
-2,020
-6% -$65.5K 0.01% 832
2025
Q1 		$1.17M Sell
34,607
-2,317
-6% -$83.1K 0.01% 822
2024
Q4 		$1.2M Buy
36,924
+2,940
+9% +$122K 0.01% 832
2024
Q3 		$1.66M Sell
33,984
-2,406
-7% -$128K 0.01% 882
2024
Q2 		$1.61M Buy
36,390
+3,030
+9% +$140K 0.01% 892
2024
Q1 		$1.87M Buy
33,360
+1,732
+5% +$104K 0.01% 909
2023
Q4 		$1.9M Buy
+31,628
New +$2M 0.01% 865

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Guggenheim Capital's LEGN Position: Q2 2026 in Review

Guggenheim Capital reduced its Legend Biotech (LEGN) stake by 31% in Q2 2026, selling an estimated $314K and leaving 26,189 shares worth $756K. The position accounts for ﹤0.01% of the portfolio, ranked #1125.

Guggenheim Capital first reported a position in LEGN in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.9M in Q4 2023. 218 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Guggenheim Capital held 26,189 shares of Legend Biotech worth $756K as of Q2 2026.
  • Guggenheim Capital sold 11,659 Legend Biotech shares in Q2 2026, an estimated $314K.
  • Legend Biotech made up ﹤0.01% of Guggenheim Capital's portfolio in Q2 2026, its #1125 holding.
  • Guggenheim Capital first reported a position in Legend Biotech in Q4 2023 and has held it in 11 quarters since.
  • Guggenheim Capital's Legend Biotech position peaked at $1.9M in Q4 2023.
  • 218 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.